Treatment of Cataplexy in Adults

First-Line Pharmacological Treatment

• The American Academy of Sleep Medicine strongly recommends sodium oxybate as the primary treatment for cataplexy in adults with narcolepsy, based on moderate-quality evidence from 6 RCTs and 6 observational studies showing clinically significant improvements in cataplexy attacks, excessive daytime sleepiness, and disease severity 1
• Sodium oxybate is administered as a liquid in two equally divided doses at night: the first dose at bedtime and the second dose 2.5-4 hours later 2
• Pitolisant (a histamine-3-receptor inverse agonist) is also effective for cataplexy management and has the advantage of not being a controlled substance 2, 3

Critical Safety Considerations for Sodium Oxybate

• Sodium oxybate carries an FDA black box warning as it is a central nervous system depressant that may cause respiratory depression; use with extreme caution in patients with respiratory conditions 2, 4
• This medication is an FDA Schedule III controlled substance (sodium salt of gamma hydroxybutyrate/GHB) and is only available through the Risk Evaluation Mitigation Strategy (REMS) program using certified pharmacies 1, 4
• Frequently reported adverse events include nausea, dizziness, nocturnal enuresis, headache, chest discomfort, sleep disturbances, and confusion 1

Second-Line Pharmacological Options

• Note that solriamfetol, armodafinil, modafinil, dextroamphetamine, and methylphenidate are recommended for excessive daytime sleepiness but do NOT directly treat cataplexy 1, 5, 6

Non-Pharmacological Management

• Maintaining good sleep hygiene and regular sleep-wake schedules can help control cataplexy 2
• Occupational considerations include avoiding shift work and on-call schedules 2

Monitoring and Follow-Up

• Regular assessment of cataplexy frequency and severity is necessary to evaluate treatment efficacy 2
• Monitor for medication side effects, particularly respiratory depression, enuresis, nausea, and headache with sodium oxybate 2, 4
• Watch for cataplexy exacerbation if any medication affecting adrenergic systems is initiated, as the loss of hypocretin-producing neurons suggests adrenergic systems are downstream mediators of cataplexy pathology 2, 3

Referral Considerations

• Primary care physicians should refer patients to a sleep specialist when narcolepsy with cataplexy is suspected for proper diagnosis and treatment initiation 2

Combination Therapy for Narcolepsy with Cataplexy

Rationale and Clinical Implementation

• The American Academy of Sleep Medicine recognizes that individualized treatment selections should be based on multiple patient factors, and clinicians commonly use medications that act via different neural pathways to achieve optimal control, with a strength of evidence based on moderate-quality evidence for individual agents 7
• Initial therapy for narcolepsy with cataplexy should begin with sodium oxybate (Xywav) as it addresses multiple core symptoms, including excessive daytime sleepiness, cataplexy, and disrupted nocturnal sleep, according to the American Academy of Sleep Medicine 8
• If excessive daytime sleepiness remains inadequately controlled, add either pitolisant or an amphetamine, as recommended by the American Academy of Sleep Medicine, with consideration of the strength of evidence for each medication 7

Safety Considerations

• When combining amphetamines with Xywav, exercise extreme caution due to the opposing CNS effects, which require careful dose titration, and monitor closely for cardiovascular effects, as amphetamines increase heart rate and blood pressure, according to the American Academy of Sleep Medicine 7
• Xywav carries an FDA black box warning as a CNS depressant that may cause respiratory depression, and its combination with amphetamines requires enrollment in REMS programs and use of certified pharmacies, as noted by the American Academy of Sleep Medicine 8
• Pitolisant is the only narcolepsy treatment not scheduled as a controlled substance by the US Drug Enforcement Administration, making it an attractive option for combination therapy, with the American Academy of Sleep Medicine guidelines supporting its use 9

Adjunctive Interventions

• Non-pharmacologic interventions, including workplace accommodations, sleep hygiene, and cognitive-behavioral therapy, remain essential adjuncts regardless of medication regimen, as recommended by the American Academy of Sleep Medicine 7

Combination Therapy for Narcolepsy with Cataplexy

Treatment Algorithm

• The American Academy of Sleep Medicine recommends initiating Xywav as foundation therapy for narcolepsy with cataplexy, as it addresses all core symptoms, including excessive daytime sleepiness, cataplexy, and disrupted nocturnal sleep, with a strength of evidence based on moderate-quality evidence from multiple RCTs 10
• Xywav carries an FDA black box warning for respiratory depression as a CNS depressant, and should be used with extreme caution in patients with any respiratory conditions, according to the American Academy of Sleep Medicine 11

Critical Safety Monitoring for Combination Therapy

• The American Academy of Sleep Medicine advises careful dose titration when combining amphetamines with Xywav due to opposing CNS effects, and monitoring of heart rate and blood pressure, as amphetamines increase both parameters while Xywav causes CNS depression 11
• The American Academy of Sleep Medicine recommends avoiding combination of Xywav with alcohol or other sedating medications due to the risk of respiratory depression 10, 11

Regulatory Requirements

• Xywav is only available through REMS programs using certified pharmacies due to its status as a Schedule III controlled substance, as regulated by the FDA and recommended by the American Academy of Sleep Medicine 10, 11

Common Adverse Effects to Monitor

• The American Academy of Sleep Medicine reports that Xywav is associated with common adverse effects including nausea, dizziness, nocturnal enuresis, headache, chest discomfort, sleep disturbances, and confusion, with rare but serious effects including central sleep apnea, depression, and suicidality 10, 11

Important Caveats

• The American Academy of Sleep Medicine advises that amphetamines do not directly treat cataplexy, and that only Xywav, pitolisant, and certain antidepressants have direct anticataplectic effects 11
• The American Academy of Sleep Medicine recommends avoiding combination therapy in pregnant or breastfeeding patients, as all three medications may cause fetal harm based on animal data, and in patients with significant cardiovascular disease, who require individualized risk-benefit assessment 10, 11

Alternative Treatment Options for Patients on XYWAV

First-Line Alternatives

• The American Academy of Sleep Medicine provides strong recommendations for solriamfetol or pitolisant as first-line alternatives for patients currently on XYWAV, with conditional recommendations for modafinil/armodafinil or traditional stimulants depending on whether cataplexy control is needed 12, 13, 14
• Pitolisant is the preferred alternative for patients with cataplexy, as it directly treats both excessive daytime sleepiness and cataplexy, with moderate-quality evidence showing clinically significant improvements in excessive daytime sleepiness, cataplexy, and disease severity across 3 RCTs 13
• Solriamfetol is the preferred alternative for patients with only excessive daytime sleepiness, with the strongest evidence base for excessive daytime sleepiness and a strong recommendation from the American Academy of Sleep Medicine based on high-quality evidence from 3 RCTs 14

Second-Tier Alternatives

• The American Academy of Sleep Medicine provides a conditional recommendation for armodafinil based on moderate-quality evidence from 1 RCT and 1 open-label study, with common adverse effects including headache, nausea, and anxiety 14
• Traditional stimulants, such as dextroamphetamine and methylphenidate, are reserved for refractory cases or when cost is prohibitive, with conditional recommendations based on very low-quality evidence and a high risk of abuse and dependence 12

Safety Considerations

• All narcolepsy medications may cause fetal harm based on animal data, with insufficient human data, and risk-benefit assessment must prioritize maternal safety and functional capacity 12, 13, 14
• Armodafinil/modafinil have documented increased congenital anomaly rates in pregnancy registries, and patients should be screened for cardiovascular disease before initiating solriamfetol or stimulants due to increased heart rate and blood pressure 14

XYWAV Titration Protocol for Narcolepsy Management

Symptom-Based Dose Optimization

• The American Academy of Sleep Medicine recommends continuing weekly titration increases until cataplexy frequency is adequately reduced, as sodium oxybate demonstrates clinically significant improvements in cataplexy control, with a focus on patients with persistent cataplexy attacks 15
• The American Academy of Sleep Medicine suggests titrating upward if daytime sleepiness remains problematic despite cataplexy control, as sodium oxybate effectively treats both symptoms, with a focus on patients with persistent excessive daytime sleepiness 15

Critical Safety Monitoring During Titration

• The American Academy of Sleep Medicine advises monitoring for respiratory depression at each dose increase, particularly in patients with underlying respiratory conditions, as XYWAV carries an FDA black box warning for CNS depression and respiratory compromise 15
• The American Academy of Sleep Medicine recommends assessing for common adverse effects, including nausea, dizziness, nocturnal enuresis, headache, chest discomfort, and sleep disturbances, at each titration step 15

Long-Term Monitoring

• The American Academy of Sleep Medicine suggests evaluating for abuse potential, as XYWAV is a Schedule III controlled substance and the sodium salt of GHB, with a focus on monitoring for signs of misuse, particularly in patients with substance abuse history 15

Patient Education and Safety

• The American Academy of Sleep Medicine emphasizes the importance of ensuring patients understand the REMS program requirements, as XYWAV is only available through certified pharmacies due to abuse potential 15